GlassScriptPhysician profile
Alice Edwards
NPI 1467895839
$111,387.37
in general payments reported to CMS, 2019-2025
17 companies · $22K in 2025
The $22K reported for 2025 was more than what 93% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $88K · 2020: $17.16 · 2021: $63.93 · 2022: $374 · 2023: $263 · 2024: $347 · 2025: $22K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $11K · Consulting Fee: $7,373 · Food and Beverage: $2,125 · Travel and Lodging: $2,069.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $11,050.00 |
| Consulting Fee | $7,373.00 |
| Food and Beverage | $2,125.01 |
| Travel and Lodging | $2,068.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $88,328.83 | 2019-2025 | Leqembi, Tysabri |
| Tg Therapeutics, INC. | $13,298.12 | 2025 | |
| Genentech USA, INC. | $8,225.36 | 2022-2025 | Ocrevus Zunovo |
| Novartis Pharmaceuticals Corporation | $347.73 | 2022-2024 | |
| Jazz Pharmaceuticals INC. | $285.89 | 2022-2024 | |
| Emd Serono, INC. | $260.61 | 2019-2025 | |
| Eisai INC. | $144.85 | 2025 | |
| Neurelis, INC. | $125.52 | 2024-2025 | Valtoco |
| Zogenix INC. | $81.09 | 2020-2021 | |
| Amgen INC. | $74.43 | 2025 | Uplizna |
| Immedica Pharma US, INC. | $51.68 | 2023-2024 | |
| Sk Life Science, INC. | $51.10 | 2024 | |
| Genentech, INC. | $35.14 | 2025 | Ocrevus |
| Averitas Pharma INC. | $28.27 | 2025 | Qutenza |
| Acadia Pharmaceuticals INC | $23.70 | 2025 | Daybue |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $14.96 | 2025 | |
| Sumitomo Pharma America, INC. | $10.09 | 2023 | Aptiom |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alice Edwards listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.